Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimer 4571 Vaccine in HIV-1 Infected Adults on Suppressive ART
NCT04985760Phase 1Completed
- Start
- Sep 2021
- Primary completion
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, triple-blind trial of trimer 4571 in human immunodeficiency virus infection (HIV) (4 arms). Primary endpoint: Safety and tolerability at Week 44. Started Sep 2021; status: completed.
02
Drugs
trimer 4571
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04985760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985760.